Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) EBT: 2017-2024

Historic EBT for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$114.7 million.

  • Denali Therapeutics' EBT rose 3.98% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.57%. This contributed to the annual value of -$422.7 million for FY2024, which is 191.13% down from last year.
  • As of Q4 2024, Denali Therapeutics' EBT stood at -$114.7 million, which was down 6.99% from -$107.2 million recorded in Q3 2024.
  • Denali Therapeutics' EBT's 5-year high stood at $245.7 million during Q4 2020, with a 5-year trough of -$119.4 million in Q4 2023.
  • For the 3-year period, Denali Therapeutics' EBT averaged around -$99.6 million, with its median value being -$102.6 million (2022).
  • Its EBT has fluctuated over the past 5 years, first soared by 555.44% in 2020, then crashed by 130.86% in 2021.
  • Denali Therapeutics' EBT (Quarterly) stood at $245.7 million in 2020, then crashed by 130.86% to -$75.8 million in 2021, then crashed by 30.13% to -$98.7 million in 2022, then dropped by 21.04% to -$119.4 million in 2023, then increased by 3.98% to -$114.7 million in 2024.
  • Its last three reported values are -$114.7 million in Q4 2024, -$107.2 million for Q3 2024, and -$99.0 million during Q2 2024.